Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) but has reduced the price target from $80 to $70.

November 13, 2023 | 5:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer has maintained an Outperform rating on Intellia Therapeutics but lowered the price target from $80 to $70, indicating a positive outlook but with tempered expectations.
While the Outperform rating suggests that Oppenheimer's analyst believes Intellia Therapeutics will perform better than the market or sector, the reduction in the price target could imply a reassessment of the company's future growth prospects or market conditions. This news is likely to be viewed neutrally by investors as the positive rating is maintained but expectations for stock price performance are moderated.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100